Mutated Cas13b with improved efficiency
By conducting deep mutation scanning and amino acid modification of the Cas13b gene, especially replacement in the non-nuclease domain, the mutated Cas13b gene and protein delivery system is formed, solving the RNA targeting efficiency and specificity of the CRISPR-Cas13b system in mammalian cells, achieving more efficient RNA targeting and inhibiting viral infection.
Patent Information
- Application Number
- CN202480008322.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-18
- Filing Date
- 2024-01-04
- Publication Date
- 2025-08-26
AI Technical Summary
There are limitations on the RNA targeting efficiency and specificity of the CRISPR-Cas13b system in mammalian cells, which affects its widespread development of clinical applications.
The Cas13b gene is modified through deep mutation scanning technology, especially multiple amino acid substitutions in the non-nuclease domain, forming a mutated Cas13b gene and protein delivery system, including virus-like particle delivery methods, enhancing its RNA-targeting function in eukaryotic cells.
It improves the RNA targeting efficiency of the CRISPR-Cas13b system in eukaryotic cells, enhances the ability to inhibit dengue virus infection, improves RNA editing and modification capabilities, and reduces the risk of side effects on host cells.
Smart Images

Figure CN120548359A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the biotechnology of mutated Cas13b genes, which are used to improve the RNA targeting activity of CRISPR-Cas13b in mammalian cells. Background Art
[0002] The CRISPR-Cas system is a system found in more than 40% of bacteria in nature. CRISPR-Cas uses a guide RNA (gRNA) or crRNA to target the Cas nuclease to DNA or RNA for cutting, and the DNA or RNA contains a sequence that can base pair with the gRNA / crRNA. The region on the gRNA / crRNA that base pairs with the target sequence is called a spacer sequence. CRISPR-Cas has been engineered for a variety of applications in gene editing and gene expression control. With these capabilities, the CRISPR-Cas system has great therapeutic application potential in treating a variety of genetic diseases caused by mutations or abnormal gene expression. In addition to its application in gene editing, some studies have shown that certain CRISPR-Cas systems can also function as antiviral molecules, which can be customized according to the genetic code of the target virus (programmable or adaptive antiviral). The CRISPR-Cas system can be applied to both DNA and RNA viruses.
[0003] CRISPR-Cas13 is one of the CRISPR-Cas systems that targets RNA. Six subtypes of the CRISPR-Cas13 system have been found in a variety of bacteria, such as VI-A (Cas13a), VI-B (Cas13b), VI-C (Cas13c), VI-D (Cas13d), Cas13X and Cas13Y subtypes. The RNA targeting function of many subtypes (except VI-C subtype) can be transferred to eukaryotic cells, such as human cells, mammalian cells, insect cells and plant cells. The binding of target RNA and Cas13-crRNA ribonucleoprotein complex (RNP) activates Cas13 nuclease activity, digesting target RNA and nearby RNA (incidental cutting). The incidental cutting of CRISPR-Cas13 can be used to develop sensitive and specific RNA detection assays. Cas13 protein can also be engineered to add new functions, such as RNA splicing control, translation regulatory factors and intracellular RNA sensors. Among the known CRISPR-Cas13 systems, CRISPR-Cas13b has been shown to have the lowest toxicity in mammalian cells and has efficient RNA targeting ability (see AiY, Liang D and Wilusz JE, (2022), CRISPR / Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells, Nucleic Acids Res. 50, e65-e65).
[0004] CRISPR-Cas13 has a variety of molecular capabilities to control and modify RNA functions in a variety of cell types and species, and therefore has received much attention in developing this system into a new therapeutic platform. However, the clinical application of CRISPR-Cas13 still requires extensive research and development to address many limitations, such as effective delivery systems for specific targeting cells or tissues, precise crRNA design algorithms, and targeting specificity and efficiency in human and mammalian cells. CRISPR-Cas is a nucleic acid targeting system that naturally functions in bacteria. Some evidence suggests that its activity may be affected in a eukaryotic environment. Studies have shown that RNA degradation in eukaryotic cells is limited and does not cause cell death as seen in prokaryotes. In the case of CRISPR-Cas13b, previous data have shown that its requirements for spacer length in mammalian cells are different from those in bacteria or in vitro. Spacer lengths shorter than the natural spacer length (30 nucleotides) (26-22 nucleotides) can enhance the activity of CRISPR-Cas13b in mammalian cells, but inhibit its function in vitro or in bacteria. Therefore, the natural version of CRISPR-Cas13 may be a suboptimal choice for therapeutic purposes.
[0005] In previous studies, it was found that the design and modification of crRNA can increase the efficiency of CRISPR-Cas13 systems in eukaryotic cells. For example, machine learning has been used to design crRNA, which is used together with CRISPR-Cas13d to knock down genes in mammalian cells (Wessels HH et al., (2020), Massively parallel Cas13 screens reveal principles for guide RNA design, Nature Biotechnology 38,722-727). Adding functional groups to the nucleotides of crRNA can help improve the stability of crRNA and increase the efficiency of knocking down. (Méndez-Mancilla et al., (2021), Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells, Cell Chem Biol 29,321-327). The use of RNA spacers of only 22-26 nucleotides can enhance the knockdown efficiency of CRISPR-Cas13b in mammalian cells (Singsuksawat et al., (2021), Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by VLP, Mol Ther-Methods Clin Dev 21, 729-740). Although these efforts have successfully increased the functional efficiency of CRISPR-Cas13 in mammalian cells, they have focused on crRNA.
[0006] Since CRISPR-Cas13 has two components: crRNA and Cas13 protein, modifying the Cas13 protein through protein engineering is a key option to increase the efficiency of this system. This property makes CRISPR-Cas13 unique compared to other forms of RNA therapy, such as RNA interference (RNAi), in which modifications to related host proteins in the pathway may have harmful side effects because they are also involved in controlling gene expression in the host cell. Therefore, modifying the Cas13 protein, which is not found in eukaryotic cells, has a much lower risk of side effects.
[0007] Because CRISPR-Cas13b possesses the most suitable cellular properties for therapeutic development among all CRISPR-Cas13 systems, improving the RNA targeting efficiency of CRISPR-Cas13b in mammalian cells through protein engineering will be an important step in transforming CRISPR-Cas13 for therapeutic development. Summary of the Invention
[0008] The present invention relates to a Cas13b gene for a mutation obtained using a deep mutation scanning (DMS) technique, the Cas13b gene for a mutation is used to improve the function of a CRISPR-Cas13b system, the invention further relates to a plasmid set for delivering a gene to the Cas13b gene for a mutation of a cell, and a protein delivery system for importing the Cas13b protein for a mutation into a target cell in the form of a virus-like particle (VLP), the protein delivery system is used to inhibit the infection of dengue virus in eukaryotic cells, wherein the PspCas13b gene obtained from a species of the bacterium Prevotella sp. is used as an example of a Cas13b gene. The PsCas13b gene for a mutation for improving the function of a CRISPR-Cas13b system comprises an amino acid modification of the PsCas13b gene, the amino acid modification of the PsCas13b gene being at least one position selected from the group consisting of: 273, 601, 570, 343, 625, 769, 990, 323, 967, 989, and 556.
[0009] In one embodiment of the invention, the amino acid modification of the Cas13b gene by replacement is at least one amino acid replacement selected from the group consisting of S273R, K601L, R570P, Y343L, T625G, N769V, K990V, K990A, D323P, I967L, N989H and T566E.
[0010] In one embodiment of the present invention, the Cas13b gene is derived from a bacterium selected from the group consisting of: Prevotella species (PspCas13b), Capnocytophaga canimorsus (CcaCas13b), Prevotella buccae (PbuCas13b), Porphyromonas gulae (PguCas13b), Prevotella species (PsmCas13b) and Riemerella anatipestifer (RanCas13b).
[0011] The plasmid set for delivering genes to the mutated Cas13b gene of cells includes: a basic plasmid pUC57-PspCas13b plasmid library for constructing a PspCas13b mutant gene library; a pLenti-CMVt-PspCas13b-eGFP plasmid library containing PspCas13b mutant genes transferred from the pUC57-PspCas13b library to the pLenti-CMVt-PspCas13b-eGFP. On pLenti-CMVt-PspCas13b-eGFP, the front end has an inducible promoter for controlling PspCas13b gene expression, and the PspCas13b gene rear end has a polyadenylic acid tail signal, and a green fluorescent gene cassette (eGFP gene cassette), which can produce green fluorescent protein (eGFP) when the plasmid is delivered to the cell. The fluorescent signal of green fluorescent protein can be used in a cell sorter to separate cells that have received the PspCas13b gene for deep mutation scanning.
[0012] The protein delivery system for importing the mutated Cas13b protein into the target cell includes virus-like particles (VLPs), which wrap the Cas13b-crRNA ribonucleoprotein complex composed of the mutated PspCas13b protein and crRNA. The mutated Cas13b protein is derived from the PspCas13b mutant gene, which is at least one amino acid replacement selected from the group consisting of the following: S273R, K601L, R570P, Y343L, T625G, N769V, K990V, K990A, D323P, I967L, N989H and T566E, wherein the mutated PspCas13b protein complex is imported into virus-like particles.
[0013] In one embodiment of the present invention, the virus-like particles for suppressing dengue virus infection of eukaryotic cells include membrane-encapsulated particles, which are made of the capsid protein of murine leukemia virus (MLV), and the particles contain Cas13b-crRNA ribonucleoprotein complexes. In addition, the surface of the envelope can accommodate other types of proteins (such as VSV-G protein), which control the combination of virus-like particles with specific cells.
[0014] The present invention discloses modifications of the amino acid sequence on Cas13b, which enhance the function of the system in eukaryotic cells relative to natural Cas13b. By performing multiple amino acid modifications on the portion of the non-nuclease domain in PspCas13b, the efficiency of the CRISPR-Cas13b platform (such as RNA editing) that does not rely on the nuclease activity of Cas13b can be increased. The results show that amino acid modifications can be used to increase the efficiency of the CRISPR-Cas13b platform that does not rely on the nuclease activity of Cas13b in function, such as stimulating the production of proteins from messenger RNA (mRNA), controlling RNA editing patterns (RNA splicing), and adding functional groups (RNA modifications) to nucleotides.
[0015] The object of the present invention is to find the modification of the Cas13b amino acid sequence that can improve the function of CRISPR-Cas13b system in eukaryotic cells relative to the Cas13b of natural version.The present invention focuses on Cas13b, because compared with other Cas13, the Cas13b has leading performance in eukaryotic cells.In addition, Cas13b, especially the Cas13b (PspCas13b) of the species from the bacterium Prevotella, can also be delivered to cells in several forms (including gene, RNA and protein delivery) by a variety of methods.PspCas13b has a high level of similarity with other Cas13b (such as PbuCas13b, RanCas13b, PguCas13b), and these other Cas13b have been engineered for multiple applications, such as locating the RNA in cells, stimulating the production of protein from messenger RNA (mRNA), controlling RNA splicing patterns, adding chemical groups (RNA modifications) and editing RNA sequences (RNA editing) on RNA.Therefore, the research data of PspCas13b are potentially applicable to these systems.
[0016] In the present invention, a gene library (PspCas13b gene library) containing PspCas13b mutants is generated, and the PspCas13b mutants collectively have single amino acid mutations at each position of each amino acid of Cas13b gene. The mutant gene library is subcloned into a lentiviral vector system, which is used to deliver PspCas13b mutant genes to BHK21-rtTA3 cells. The BHK21-rtTA3 cells have a reporter gene for fluorescent protein mCherry and crRNA (mCh3 crRNA) targeting mCherry, thereby producing a cell library with a PspCas13b mutant library. After the PspCas13b gene set is delivered to cells by lentiviral transduction, fluorescence-activated cell sorting (FACS) is used to select cells with both PspCas13b genes and carrying RNA (carrying RNA), and then cultured for three days before another round of cell sorting. In the second round of cell sorting, cells were sorted by the fluorescence level of mCherry, which was used as an indicator of the knockdown activity level of the CRISPR-Cas13b system. Cells with mCherry fluorescence levels in the lowest 20% of the total cell population were selected, and the frequency of each PspCas13b mutant was analyzed by deep sequencing. The frequency value was then used to calculate an enrichment score that represents the knockdown performance of each PspCas13b mutant. As a result of using the present invention, a database of the effects of PspCas13b mutations on the RNA targeting function of the CRISPR-Cas13b system was obtained. The PspCas13b mutant library covers approximately 20,000 amino acid mutations of the PspCas13b gene, and the database is used to modify the amino acid sequence of PspCas13b to increase the RNA targeting efficiency of PspCas13b in eukaryotic cells.
[0017] Data from this analysis were used to modify Cas13b in a previously developed VLP-Cas13b system and found that this modification of Cas13b could increase the efficiency of VLP-Cas13b in inhibiting dengue virus infection by up to fourfold in BHK21 cells, where dengue virus can replicate rapidly because the cells lack the antiviral interferon system to slow viral replication.
[0018] Since many enhancing mutations of PspCas13b are located in a domain (non-nuclease domain) that does not have the function of cutting RNA, but may play other roles in RNA targeting function, the present invention tests whether these mutations can enhance the efficiency of other CRISPR-Cas13b systems that do not rely on RNA cutting function or nuclease activity. It was found that some mutations can be used to increase the RNA editing efficiency of CRISPR-Cas13b systems. The results of RNA editing show that the mutation can increase the efficiency of other CRISPR-Cas13b systems, such as locating the RNA in cells, stimulating the production of proteins from messenger RNA (mRNA), controlling RNA splicing patterns, and adding chemical groups (RNA modifications) to RNA. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Shown is one version of a method for generating a library of PspCas13b mutant genes and for generating a library of lentiviral plasmids containing mutant PspCas13b genes.
[0020] Figure 2 Schematic illustration of the method for deep mutation scanning of PspCas13b in BHK21-rtTA3-crRNA by fluorescence-activated cell sorting (FACS).
[0021] Figure 3 The histogram shows that Figure 2 The average of the enrichment scores obtained in the deep mutation scans is shown.
[0022] Figure 4 Display from Figure 2 Correlation between the enrichment scores of two replicates of deep mutational scanning is shown.
[0023] Figure 5 The WebLogo diagram shows the Figure 2 Average enrichment scores for each PspCas13b mutation from two replicates of deep mutational analysis are shown.
[0024] Figure 6 Showing the tolerance of PspCas13b to amino acid mutations in the structure of the PbuCas13b protein that binds crRNA.
[0025] Figure 7The knockdown activity of CRISPR-Cas13b mutants in inhibiting mCherry expression was measured by the relative intracellular mean fluorescence intensity (MFI) between mutant Cas13b and wild type. The relative intracellular MFI is designated as KD. A low KD value indicates that the fluorescence intensity of the CRISPR-Cas13b mutant is lower than that of the original CRISPR-Cas13b, meaning that the CRISPR-Cas13b mutant has a higher knockdown efficiency than the original system.
[0026] Figure 8 The knockdown activity of CRISPR-Cas13b mutants against mCherry expression was measured by the relative dengue virus infection percentage between mutant Cas13b and wild-type. The relative dengue virus infection percentage is designated as % KD. A low % KD value indicates that the degree of viral infection in cells with the CRISPR-Cas13b mutant is lower than that in cells with the original CRISPR-Cas13b, indicating that the CRISPR-Cas13b mutant has higher knockdown efficiency than the original system.
[0027] Figure 9 The modified amino acid positions (e.g., Figure 7 shown).
[0028] Figure 10 (A) Relative MFI of mCherry fluorescence indicates the increase in the amount of fluorescent dengue virus in BHK21 cells.
[0029] (B) Graph depicting the fold increase in the efficiency of inhibiting dengue mCherry reporter virus infection in cells containing PspCas13b with the R570P mutation and several crRNAs (e.g., crRNA-8681, crRNA-8675, and crRNA-8678), with mCh3 crRNA and mAmet1 crRNA serving as positive and negative controls, respectively.
[0030] Figure 11 We show that the use of a Cas13b mutant with the R570P mutation and crRNA-8678 enhances the ability to protect BHK21 cells from cell death induced by dengue virus 2 infection, whereas the original PspCas13b (WT) fails to prevent cell death.
[0031] Figure 12The figure shows a comparison of the ratio of the amount of Cas13b in cells infected with dengue virus and the percentage of dengue virus-infected cells in the VLP-Cas13b system modified with R570P amino acid and the VLP-Cas13b system without amino acid modification (WT).
[0032] Figure 13 Showing the enhanced effect of RNA editing by CRISPR-Cas13b using PspCas13b with the R570P mutation.
[0033] (A) The percentage of cells receiving Cas13b is plotted to demonstrate that similar levels of plasmid containing the PspCas13b gene were delivered to 293T cells under each experimental condition.
[0034] (B) Graph showing the number of cells undergoing RNA editing of the target RNA as measured by an increase in GFP levels.
[0035] (C) Graph showing the increase in the average brightness level or relative fluorescence intensity of GFP during RNA editing using PspCas13b with the R570P mutation.
[0036] Figure 14 Graph illustrating the ability of PspCas13b with the R570P mutation in combination with amino acid modifications at other positions to disruptively knock down mCherry. DETAILED DESCRIPTION
[0037] The present invention relates to a mutant Cas13b gene for improving CRISPR-Cas13b system function, a plasmid set for delivering a gene to a mutant Cas13b gene of a cell, and a protein delivery system for importing mutant Cas13b protein into a target cell in the form of virus-like particles (VLPs), wherein the protein delivery system is used to suppress the infection of dengue virus in eukaryotic cells, wherein the PspCas13b gene obtained from the species of bacterium Prevotella is an example of a Cas13b gene. However, the application does not limit the source of Cas13b gene in any way. The personnel of the ordinary professional knowledge level can know that the source of the Cas13b gene used can be adjusted or changed within the scope of the appended claims.
[0038] The present invention discloses the modification of the amino acid sequence on Cas13b, and the modification enhances the function of the system in eukaryotic cells relative to natural Cas13b. By performing multiple amino acid modifications on the portion of the non-nuclease domain in PspCas13b, the efficiency of the CRISPR-Cas13b platform (such as RNA editing) that does not rely on the nuclease activity of Cas13b can be increased. The results show that amino acid modification can be used to increase the efficiency of the CRISPR-Cas13b platform that does not rely on the nuclease activity of Cas13b in function, such as stimulating messengers to produce proteins from RNA (mRNA), controlling RNA editing patterns (RNA splicing), and adding functional groups (RNA modifications) to nucleotides.
[0039] Mutated Cas13b genes for improving the function of the CRISPR-Cas13b system
[0040] A mutated Cas13b gene for improving the function of the CRISPR-Cas13b system, characterized in that the amino acid modification of the PsCas13b gene is at at least one position selected from the group consisting of: 273, 601, 570, 343, 625, 769, 990, 323, 967, 989 and 556.
[0041] In one embodiment of the invention, amino acid modification is achieved by a method selected from replacement, deletion and addition.Wherein the amino acid modification by replacement is at least one amino acid replacement selected from the group consisting of the following: S273R, K601L, R570P, Y343L, T625G, N769V, K990V, K990A, D323P, I967L, N989H and T566E (residue numbering is based on PspCas13b gene). In one embodiment of the invention, Cas13b gene is derived from a bacterium selected from the following: species (PspCas13b) of Prevotella, Capnocytophaga canimans (CcaCas13b), Prevotella cheek (PbuCas13b), Porphyromonas gingivalis (PguCas13b), species (PsmCas13b) of Prevotella and Riemerella anatipestifer (RanCas13b).
[0042] Table 1 shows the amino acid positions of Cas13b obtained from other microorganisms. The positions of CcaCas13b, PbuCas13b, PguCas13b, PsmCas13b, and RanCas13b are equivalent to PspCas13b.
[0043]
[0044] According to Table 1, the position of the 273rd amino acid of PspCas13b is respectively equivalent to the 341st of CcaCas13b, the 287th of PbuCas13b, the 276th of PguCas13b, the 338th of PsmCas13b and the 264th of RanCas13b. Therefore, it is known that the personnel with average professional knowledge level in the relevant scientific field can modify equivalent amino acid positions to produce the Cas13b gene of mutation from other microorganisms. The example of the Cas13b gene of the species from Prevotella with mutation is only an example representing the essence of the present invention (while in the form of the Cas13b gene, plasmid kit and delivery system of mutation), but is not limited in any way to only using the Cas13b gene of the species from Prevotella.
[0045] Plasmid set for mutated Cas13b gene for gene delivery to cells
[0046] The plasmid set for delivering the mutated Cas13b gene to cells contains:
[0047] A. A mutated Cas13b gene, characterized in that the amino acid modification of the Cas13b gene is at at least one position selected from the group consisting of S273R, K601L, R570P, Y343L, T625G, N769V, K990V, K990A, D323P, I967L, N989H and T566E, and
[0048] B. Lentiviral vector,
[0049] The mutated Cas13b gene is constructed into a lentiviral vector.
[0050] In one embodiment of the present invention, the plasmid set for delivering the gene to the mutated Cas13b gene of the cell further comprises: a polyadenylic acid tail signal connected to the mutated Cas13b gene, and a gene set for producing a luminescent protein, which is used to track the cells receiving the mutated Cas13b gene by the presence of a fluorescent protein in the cell. The luminescent protein is selected from green fluorescent protein (eGFP), red fluorescent protein (mCherry) and infrared fluorescent protein (miRFP703).
[0051] In each component, additional details are as follows:
[0052] The amino acid modification of the Cas13b gene included in the Cas13b gene of mutation is at least one amino acid replacement selected from the group consisting of the following: S273R, K601L, R570P, Y343L, T625G, N769V, K990V, K990A, D323P, I967L, N989H and T566E (residue numbering is based on PspCas13b gene). These PspCas13b mutant genes can be constructed by carrying out site-directed mutagenesis to pUC57-PspCas13b plasmid.
[0053] The lentiviral vector pLenti-CMVt-PspCas13b-eGFP contains: a long terminal region (LTR); a packaging signal (psi) site for packaging RNA transcribed from pLenti into viral particles for delivering the target gene (PspCas13b in this case), which is controlled by an inducible promoter at the front end of the PspCas13b gene and a polyadenylic acid tail signal at the rear end of the PspCas13b gene; and an expression cassette that expresses a selected fluorescent protein marker (e.g., green fluorescent protein (eGFP)) when the PspCas13b gene is delivered to the nucleus. The fluorescent signal of green fluorescent protein can be used in a cell sorter to separate cells that have received the PspCas13b gene for deep mutation analysis.
[0054] In one form, the mutant PspCas13b gene on the pUC57-PspCas13b plasmid was replicated as a DNA fragment by PCR and used to replace the PspCas13b gene on the pLenti-CMVt-PspCas13b-eGFP. The pLenti-CMVt-PspCas13b-eGFP mutant plasmid library was then transfected into 293T cells together with the psPAX2 plasmid and the pCMV-VSV-G plasmid to produce lentiviral particles for delivering the mutant PspCas13b gene to other cells to test the function of the PspCas13b gene.
[0055] The PspCas13b mutant gene library includes a series of pLenti-PspCas13b plasmids, the plasmid has a mutant PspCas13b gene and a GFP gene, the mutant PspCas13b gene is controlled by the transcription of the TRE promoter induced by doxycycline, and the GFP gene is used to sort (cell sorting) cells that have received mutant PspCas13b genes, and the cells are used to measure the activity of PspCas13b mutants. The crRNA box is delivered by lentiviral particles derived from pBA439-PspCas13b-crRNA plasmids. The crRNA box is composed of the crRNA gene for programming the RNA target of PspCas13b and the miRFP703 fluorescent marker gene for isolating the cells that have received crRNA genes. PspCas13b mutant genes are produced by site-directed mutagenesis using the Gibson assembly method.
[0056] Protein delivery system for introducing mutant Cas13b proteins into target cells
[0057] The delivery system for the mutant Cas13b protein comprises:
[0058] A) virus-like particles, and
[0059] B) a specific protein complex (Cas13b-crRNA ribonucleoprotein complex), which includes Cas13b mutant protein, CRISPR-Cas13 system and crRNA, which are in the form of ribonucleoprotein complex (Cas13b-crRNA complex). The mutated Cas13b protein can be obtained from the mutated Cas13b gene, characterized in that:
[0060] The amino acid modification of the Cas13b gene is at least one amino acid replacement selected from the group consisting of S273R, K601L, R570P, Y343L, T625G, N769V, K990V, K990A, D323P, I967L, N989H and T566E.
[0061] The specific protein complex is contained in virus-like particles.
[0062] In one embodiment of the present invention, the virus-like particles (VLPs) comprise: a capsid protein from a murine leukemia virus, which is used to encapsulate a specific Cas13b protein; and a cell membrane from a 293T cell, which has a surface protein specific to a target cell, and the surface protein is used to allow the VLP to bind to the target cell.
[0063] The mutant Cas13b protein is delivered using a virus-like particle (VLP). VLP uses membrane proteins on the envelope to bind to the cell surface molecules of the target cell, thereby delivering the mutant Cas13b protein, and the envelope is obtained from 293T production cells. Other proteins (such as VSV-G) can be inserted into the envelope of VLP to program the target cells delivered by VLP.
[0064] The VLP bound to the target cell surface is taken up by the cell through endocytosis, which peels off the envelope from the VLP particle, thereby delivering the inner nucleocapsid that wraps the mutant PspCas13b-crRNA complex. Once in the cytoplasm, the nucleocapsid disintegrates and releases the PspCas13b-crRNA complex into the cytoplasm. The Cas13b-crRNA ribonucleoprotein complex can then approach the intracellular target RNA.
[0065] The virus-like particles used to inhibit dengue virus infection in eukaryotic cells are composed of virus-like particles obtained by protein precipitation of the culture medium of 293T production cells with polyethylene glycol 8000. The 293T production cells are transfected with four plasmids that produce key components of VLPs containing PspCas13b-crRNA, namely pCMV-VSV-G, pGAG-POL, pGAG-PspCas13b and pC0043-PspCas13b-crRNA. The pGAG-POL plasmid encodes the constituent proteins of the VLP nucleocapsid. The murine leukemia virus capsid protein selected for VLP is assembled into hollow particles, and the hollow particles are filled with Cas13b and crRNA. The capsid particles are wrapped by an envelope derived from 293T production cells. The outer surface of the envelope contains proteins from cells used to produce VLPs. One of the inserted proteins is the VSV-G protein made from the pCMV-VSV-G plasmid, and enables the VLP to bind to specific cells that are targets for Cas13b delivery. The pGAG-PspCas13b plasmid and the pC0043-PspCas13b-crRNA plasmid were used to produce PspCas13b and crRNA encapsulated in virus-like particles, respectively.
[0066] Example of PspCas13b mutant gene library design and construction
[0067] Design and construct PspCas13b mutant genes to obtain a PspCas13b mutant gene library, which can be effectively used in various application forms of CRISPR-Cas13b in controlling and modifying RNA functions, especially in eukaryotic cells, such as inhibiting RNA expression (knockdown), changing the RNA genetic code (RNA editing), and stimulating protein production from mRNA, controlling RNA splicing patterns (RNA splicing), adding functional groups to RNA nucleotides (RNA modification), etc.
[0068] For designing mutation Cas13b gene library, computer program can be used to analyze mutation.In the present invention, deep mutation scanning (DMS) technology is used to analyze mutant gene library.It is known to the personnel with professional knowledge in the relevant scientific field that the steps involved can be improved or modified, or other forms or technologies for analyzing mutation are selected and used interchangeably or together.
[0069] For preparing mutant Cas13b libraries for DMS, the simplified steps are as follows:
[0070] Figure 1 The strategy for generating a mutant PspCas13b gene library by dividing the PspCas13b gene into 55 frames, each with 20 amino acids. Within each frame, each position was mutated to 19 other amino acids. Since the PspCas13b gene is 1,100 amino acids long, there are a total of 20,900 single amino acid mutants in the PspCas13b gene library.
[0071] A plasmid library containing a mutant gene of PspCas13b was constructed. 55 groups of pUC57-PspCas13b, each group covering one mutation site at a time within the framework of its 20 consecutive amino acid positions: plasmid library group 1 starts from the 1st amino acid position of PspCas13b to the 20th amino acid position, plasmid library group 2 covers amino acid positions 21 to 40 of PspCas13, until plasmid library group 55 covers amino acid positions 1081 to 1100. These plasmid library groups were generated by site-directed mutagenesis of every 20 amino acid positions of PspCas13b covered by the sublibrary group using the Gibson assembly method. The Gibson assembly method introduces mutations by replacing the original DNA sequence of PspCas13b with a synthetic DNA fragment containing a specific mutation in the PspCas13b gene on the plasmid pUC57-PspCas13b. Then, the mutant plasmid group is transformed into DH10B bacteria in a tube together, and the transformed bacteria are grown at 30 degrees Celsius (℃) overnight in LB medium containing 100 micrograms per milliliter (μg / ml) of ampicillin, and then the plasmid is extracted using bacteria. Each amino acid mutation design uses only the codon with the highest frequency in human codons. The design is used to minimize the size of the plasmid library and the scale of the experiment, and to improve the accuracy of the amino acid mutation frequency measurement during the DMS process. In addition to the amino acid mutations in the group, each plasmid group also includes mutations (synonymous mutations) that do not change the amino acid but change the DNA sequence at every 20 mutation sites. These synonymous mutations are used as references (negative controls) for neutral mutation effects during the DMS process.
[0072] All 55 pUC57-PspCas13b groups together have mutations at all 1100 amino acid positions in the PspCas13b gene. A total of 20,900 amino acid mutations and 1,662 synonymous mutations. The number and frequency of these mutations were confirmed by deep sequencing of the plasmid library. The pUC57-NS5 plasmid used to generate the NS5 mutant library was obtained by cloning a PspCas13b fragment containing the NES and HA tags from plasmid pC0046 (addgene #103862) and inserting it into pUC57.
[0073] From 55 groups of PspCas13b gene mutants on the pUC57-PspCas13b plasmid, the PspCas13b mutant gene is cloned into a lentiviral plasmid to replace the PspCas13b gene, and a lentiviral vector for delivering the PspCas13b gene library to cells is produced, and the cells are used for DMS. The plasmid used to produce the lentiviral plasmid library is the previously constructed pLenti-CMVt-PspCas13b-eGFP (Singsuksawat et al., (2021), Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by VLP, Mol Ther-Methods Clin Dev 21, 729-740). The mutant PspCas13b gene from the pUC57-PspCas13b sublibrary adjacent to the two groups of amino acid positions is used to replace the original PspCas13b gene on pLenti-CMVt-PspCas13b-eGFP, and a group of PspCas13b lentiviral sublibraries are constructed by Gibson assembly technology. A group of assembled (by Gibson assembly) lentiviral vector plasmid library is transformed into DH10B bacteria (one tube per group of plasmids) by electroporation. Then, the electroporated bacteria are grown overnight at 30°C in LB medium containing 100 micrograms per milliliter (ug / ml) of ampicillin, and then the plasmid is extracted using bacteria. The pLenti-CMVt-PspCas13b-eGFP lentiviral plasmid library group is used to produce a lentiviral library, which is used to deliver the PspCas13b mutant gene to cells, in which the effect of the mutation on the RNA targeting function of PspCas13b is analyzed.
[0074] To measure the effect of mutations on the RNA targeting function of PspCas13b by DMS, the cell fluorescence intensity indicating the expression level of the mCherry gene was used as a measure. CrRNA targeting mCherry mRNA was used together with PspCas13b, and the crRNA was designed and previously tested to reduce the expression (or cell fluorescence intensity) of the mCherry gene. For DMS, an mCherry targeting crRNA with a spacer length of 22 nucleotides was used. To verify the single PspCas13b mutant selected by DMS, an mCherry targeting crRNA with a spacer length of 30 nucleotides was used. The sequences of the above two crRNAs have been reported in the work of Singsuksawat and colleagues (Singsuksawat et al., (2021), Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by VLP, Mol Ther-Methods Clin Dev 21, 729-740) and in the work of Marina et al. (Marina et al., (2020), Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing, Cell Reports 33).
[0075] Example 1: Deep mutation scanning analysis using the PspCas13b gene mutation set
[0076] The method for measuring the efficiency of mutation-directed target RNA destruction using a set of PspCas13b gene mutations can be summarized in Figure 2In the initial step, BHK21-rtTA3 cells were engineered to contain both the mCherry reporter gene and a target RNA carrying the base sequence on the mCherry gene. This was achieved by delivering the mCherry gene and target RNA to BHK21-rtTA3 cells using a lentiviral system. The mCherry gene is placed under the control of the PGK promoter, allowing continuous expression, while the target RNA is controlled by the mouse U6 promoter and paired with the miRFP703 gene cassette for the red fluorescent protein biosensor. The cells were then sorted using fluorescence-activated cell sorting (FACS) to isolate cells containing both components, which were used to test the PspCas13b gene mutation set. Next, mCh3crRNA targeting RNA with a spacer sequence of 22 nucleotides was used for testing, which has been previously demonstrated and reported (Singsuksawat et al., (2021), Potent programmable antiviral against dengue virus in primary human cells byCas13b RNP with short spacer and delivery by VLP, Mol Ther-Methods Clin Dev 21, 729-740). Throughout the experiment, cells were cultured in Dulbecco's modified eGaLe medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS).
[0077] The pLenti-PspCas13b plasmid containing the PspCas13b mutant gene is used to produce a lentivirus, which imports the gene set into BHK21-rtTA3-mCherry-mCh3 / 22nt-crRNA cells. Lentivirus-mediated delivery includes importing two boxes of PspCas13b and eGFP into transduced cells. The delivery is carefully implemented to achieve about 20-40% of the cells in the total cell population expressing GFP, ensuring that about 95% of the cells receive no more than one copy of the PspCas13b gene. Three days after gene delivery, fluorescence-activated cell sorting (FACS) is used to select cells incorporating the PspCas13b gene (marked by GFP). Subsequently, the selected cells are cultured for another three days, and then doxycycline at a concentration of 100 ng / ml is introduced to induce PspCas13b gene expression. Three days later, FACS is used to sort the induced cells according to the cell mCherry fluorescence level. The target cells selected are the 20% with the lowest mCherry fluorescence in the entire cell population, indicating that these cells have the highest RNA knockdown activity (top 20%). In theory, the selected cell group is expected to enrich effective PspCas13b mutant genes compared to their original gene frequencies before cell selection. Determining the frequency of PspCas13b mutant genes involves deep sequencing of the PspCas13b genes of the selected cell group and all cells before mCherry FACS. This process provides read counts of each mutant gene and wild-type gene in the two gene libraries. The mutation frequency of each gene is then calculated by dividing the read count of the mutant gene by the total read count of the corresponding wild-type gene in the same gene library.
[0078] In the process of deep sequencing, genomic DNA was extracted from the cell group using a genomic DNA extraction kit. The genomic DNA obtained was used as a PCR template to amplify the position of the PspCas13b gene through mutation into short DNA fragments. The quantity of these amplicons was measured using Nanodrop and Qubit. Then, the short DNA fragments (amplicons) produced by the PspCas13b gene of each group of mutations in a total of 28 groups were merged into one tube in nanogram equivalents. The combined sample was used for deep sequencing. Deep sequencing data includes the base sequence of the DNA fragment representing the gene of the mutation, and the read count of the gene of each mutation in each gene set.
[0079] The deep sequencing data in fastq file format is filtered to select high-quality sequence reads with a Q score>30. The double-end reads from both directions are merged into single-base sequences. The sequences of each paired read are merged, and the DiMSum program is used to count the reads of similar base sequences (Faure AJ et al., (2020), DiMSum:an error model and pipeline for analyzing deep mutational scanning data and diagnosing common experimental pathologies, Genome Biology 21,207). In this data management step, after obtaining the processed data, each mutation pattern is quantified by counting the number of reads of the pattern. The data is converted into a table using a customized Python script, which includes information such as each mutation pattern, the amino acid position of the mutation, and the read count. The table is then used to calculate the frequency of each mutant gene in each cell group.
[0080] The enrichment score is determined by taking the logarithm of the ratio of the mutation frequency after selection to the mutation frequency before selection with a base of 2. A positive enrichment score indicates that the mutation frequency in the selected cell group (top 20%) has increased, indicating that the efficiency of PspCas13b in inhibiting mCherry in this group has increased. Conversely, a negative enrichment score indicates that the mutation frequency in the selected cell group (top 20%) has decreased, indicating that the mutation in this group has weakened the efficiency of PspCas13b in inhibiting mCherry.
[0081] The above-mentioned deep mutation scanning analysis was repeated twice, and the results were analyzed for reproducibility. The data showed a high degree of similarity, with a Pearson correlation coefficient of 0.67 between the two analyses (see Figure 4 The results of the deep mutation scanning analysis are summarized in the WebLogo diagram (see Figure 5 ), where measurements were taken from 14,046 mutations. The height of the letters in the WebLogo indicates the frequency of each mutation.
[0082] Figure 5 The WebLogo diagram in the figure illustrates the enrichment score size of the above mutation frequency at each amino acid position of the PspCas13b protein in the selected cell group (top 20%). The letters above the horizontal axis correspond to mutations that contribute positively to the enrichment score, indicating that the mutation enhances the effectiveness of PspCas13b function. On the other hand, the letters below the horizontal axis represent mutations that contribute negatively to the enrichment score, indicating that the mutation weakens the efficiency of PspCas13b function in the top 20% group. It should be noted that Figure 5The letters below the middle horizontal axis are reduced in size by four times compared to the actual enrichment score size to enhance the visibility of the letters above the axis.
[0083] from Figure 5 It is clear from the data that most mutations are either deleterious or have no effect on the function of PspCas13b, especially mutations in the HEPN2 domain region that functions as the nuclease domain. Figure 3 The average enrichment score size of the histogram indicated that only 19 mutations could potentially enhance the functional efficiency of PspCas13b. Figure 4 Figure 3 (shown in Figure 3) shows mutations that have previously been identified to hinder the function of PbuCas13b at some positions. For example, amino acid positions 131-136 and 1053-1058, which accelerate RNA cutting in HEPN1 and HEPN2, are positions that are intolerant to mutations. Examples of such positions include 537, 539, 560, 723, 724, 727, 732, 880, 881, and 884, which are related to RNA binding. These positions are susceptible to mutations that adversely affect Cas13b function. Figure 6 Calculate the mutation tolerance of PbuCas13b structure from Figure 6 The data in the study observed that the nuclease domain containing HEPN1 and HEPN2 was not very tolerant to mutations. In addition, some interacting regions, such as the LID region and the HEL2 region, and the HEPN2 region and the HEL1 region, were also not tolerant to mutations. This indicates the importance of these interactions for PspCas13b function and suggests that PspCas13b amino acid modifications in these regions should be avoided in order to enhance the efficiency of PspCas13b.
[0084] Example 2: Evaluation of the performance of modified PspCas13b in eukaryotic cells
[0085] refer to Figure 5 , a total of 62 mutations were intentionally selected to evaluate their effects on enhancing PspCas13b function. This selection was intended to avoid bias associated with RNA targets or the deep mutation scanning system used for analysis. For the selected mutations, an mCherry-targeting crRNA (mCh3 crRNA) with a spacer sequence length of 30 nucleotides was used to test the reporter dengue virus with an mCherry gene. The experimental setup differs from the setup used in the deep mutation scanning analysis in terms of crRNA and reporter gene constructs. The evaluation was performed in BHK21 cells, where dengue virus can replicate at high levels.
[0086] To test 62 mutations in the PspCas13b gene, as described in Example 1, lentiviral vector system engineering BHK21-rtTA3 cells were used to express the mCh3 crRNA with a spacer sequence of 30 nucleotides. The cells were then sorted using fluorescence-activated cell sorting (FACS) to isolate cells expressing miRFP703 fluorescent protein, which demonstrated the presence of crRNA boxes. Subsequently, as described in detail in Example 1, the Cas13b lentiviral vector system was used to deliver the mutated PspCas13b gene to the BHK21-rtTA3 cells with mCh3 crRNA. FACS was used to sort cells again, and this time cells expressing green fluorescent protein (GFP) were selected, demonstrating the successful delivery of the PspCas13b gene and the complete reconstruction of the CRISPR-Cas13b system in the cells.
[0087] After obtaining cells with the CRISPR-Cas13b system, PspCas13b gene expression was induced for 24 hours by adding doxycycline at a concentration of 100 ng / ml. Subsequently, the cells were infected with a dengue reporter virus with the mCherry gene at an infection multiplicity (MOI) of 0.1, and the cells were cultured for another three days. Before collecting the cells for analyzing the mCherry fluorescence level, the cells were treated with 2% formaldehyde at room temperature for 10 minutes and then washed twice with phosphate-buffered saline (1xPBS) for preservation. The cells were then placed on ice, and the fluorescence levels were measured by flow cytometry. This analysis is intended to assess the degree of inhibition of viral infection, with the mCherry fluorescence signal as an indicator.
[0088] from Figure 7 and Figure 8 The experimental results shown observed that, overall, the selected mutant gene sets showed enhanced efficiency in inhibiting dengue virus infection at different levels. Among the 62 mutant PspCas13b genes, some showed improved inhibition compared to wild-type PspCas13b, achieving an inhibition of about 40% or more. Notably, mutations S273R, K601L, R570P, Y343L, T625G, K990V, K990A, D323P, I967L, N989H, and T566E showed particularly high levels of inhibition.
[0089] Among the mutants tested, the R570P mutation stood out, with the highest enhancement level, achieving nearly fourfold improvement compared to wild-type PspCas13b. Figure 9As shown, R570P is located outside the nuclease domain of Cas13b. Therefore, it is conceivable that R570P can enhance the efficiency of other CRISPR-Cas13 systems that do not rely on nuclease activity for their function. These systems may be involved in a variety of RNA-related cellular processes, including RNA localization, stimulating protein production from messenger RNA (mRNA), controlling RNA splicing patterns, regulating RNA modifications to nucleotides, and RNA editing. Therefore, the research team continued to conduct additional experiments to further investigate the impact of R570P.
[0090] The test of R570P to inhibit dengue virus infection was carried out using three different dengue virus-targeted crRNAs: crRNA-8681, crRNA-8675 and crRNA-8678, which have been previously reported. The three crRNAs have different abilities to inhibit dengue virus, with crRNA-8681 showing the ability to protect BHK21 cells from virus-induced cell death, while the other two crRNAs cannot prevent cell death. In order to test how R570P enhances the antiviral activity of crRNA, BHK21-rtTA3 cells were transduced with lentivirus, which delivered crRNA and R570PCas13b as described above. Then, cells were sorted using fluorescence-activated cell sorting (FACS) to select cells with a complete CRISPR-Cas13b system. Subsequently, 24 hours before infection with dengue virus, the selected cells were induced with doxycycline (100 ng / ml). In the initial phase of the assay, the dengue virus used expressed mCherry, allowing for evaluation of the enhanced efficiency of the three guide RNAs combined with R570P Cas13b. This evaluation was performed using a previously described assay.
[0091] Figure 10 (A) shows the relative mean fluorescence intensity (RFI) of mCherry fluorescence, indicating the level of viral replication in infected BHK21 cells. It was observed that R570P Cas13b enhanced the inhibitory effect against dengue virus when using various types of RNA guides, as shown by red fluorescence, compared to the original Cas13b (WT). In addition, when using non-targeting mAmet1 crRNA, R570P Cas13b maintained a specific and potent inhibitory effect, as the mCherry fluorescence level showed no significant difference between WT and R570P Cas13b.
[0092] from Figure 10The histogram shown in (B) clearly shows that R570P Cas13b can effectively inhibit dengue virus infection, although at different levels. It was observed that crRNA-8678 had the highest efficiency. BHK21-rtTA3 cells with crRNA-8678 and R570P Cas13b were then tested for dengue virus serotype 2 strain 16681, which can kill BHK21 cells after infection. Compared with BHK21-rtTA3 cells with crRNA-8678 and original Cas13b. The results show that the original PspCas13b gene and crRNA-8678 (WT) cannot prevent cell death caused by infection, but R570PCas13b and crRNA-8678 can effectively protect cells from virus-induced cell death (such as Figure 11 (shown in the micrograph).
[0093] Example 3: Use of R570P-modified virus-like particles (VLP-Cas13b) to inhibit dengue virus infection in BHK21 cells.
[0094] In view of the relevant findings of delivering R570P Cas13b to cells in the form of genes in previous tests, it is necessary to explore alternative delivery methods that do not induce permanent changes to the cell genome. To this end, the research team used R570P Cas13b protein delivered by virus-like particles (VLPs) for testing. The delivery system (VLP-Cas13b) was previously developed by the team. The modification process involves changing the DNA sequence of the Gag-Cas13b plasmid to produce R570P Cas13b VLP. These VLPs encapsulate Cas13b-crRNA complexes. The cells were co-transfected with plasmids Gag-Cas13b (5.1 μg), pBS-CMV-Gag-Pol (8.4 μg), pVSVG (3.3 μg) and pC0043-crRNA (13.2 μg) mixed in a volume of 500 μL of serum-free medium at 150 cm 2 VLPs were produced in 15 million 293T cells in a cell culture dish for 24 hours. The DNA-PEI complex was added to 293T cells. After incubation for 48 hours at 37°C and 5% CO2, the VLPs were collected and separated by centrifugation and filtration. After separation, the VLPs were concentrated and the Cas13b levels were quantified using an enzyme-linked immunosorbent assay (ELISA). The Cas13b protein in the VLPs was detected by the HA tag on Cas13b. This method allows the use of R570P Cas13b to inhibit dengue virus infection while avoiding permanent genomic changes. The successful production of R570P Cas13b VLPs indicates that this is a potential delivery method for Cas13b that does not induce lasting changes in the cellular genome.
[0095] By mixing the corresponding amount of VLP by the required amount of Cas13b (PspCas13b), the delivery of the Cas13b-crRNA complex by VLP is completed. In the presence of polybrene (8 μg / ml) in the cell culture medium, VLP is added to the cells with a final volume of 100 μL. The mixture is added to a 24-well plate containing 100,000 to 200,000 cells. After adding VLP, the cells are incubated for 4 hours. After incubation, a dengue reporter virus expressing mCherry is introduced with an infection multiplicity (MOI) of 0.1. The cells are then incubated for another 3 days, and the cells are collected for flow cytometry analysis to assess the mCherry fluorescence indicating the level of viral replication.
[0096] like Figure 12 As shown, from the comparison of the dengue virus inhibition effect of different VLP-Cas13b amounts, it was observed that the amount of Cas13b required for VLP-R570PCas13b was approximately 4.5 times lower than that of the original VLP-Cas13b (WT), achieving comparable viral inhibition levels. Therefore, when the Cas13b system is delivered as a protein, R570P can enhance the viral inhibition efficiency of the Cas13b system.
[0097] Example 4: Use of R570P-modified dCas13b-ADAR2DD for RNA editing in eukaryotic cells.
[0098] Since R570P is located in the HEL1 domain that does not function as a nuclease domain, we investigated whether R570P could enhance the efficiency of a CRISPR-Cas13 system that does not rely on nuclease activity, termed deactivated Cas13 (dCas13).
[0099] Although inactivated Cas13 (dCas13) cannot destroy the target RNA, it retains the ability to use crRNA to guide dCas13 to bind to the target RNA. Therefore, by fusing dCas13 with a variety of proteins (such as luminescent proteins, proteins that control RNA splicing, proteins that control protein synthesis from target RNA, and enzymes that modify the chemical structure of bases on RNA for RNA editing), it is possible to generate a universal CRISPR-Cas13 system for a variety of applications, such as RNA imaging to monitor the location of RNA in cells, controlling RNA splicing, regulating protein synthesis from target RNA, and modifying the genetic information of target RNA through RNA editing.
[0100] By measuring the GFP fluorescence level produced by editing GFP mRNA sequence, the ability of R570P mutation to enhance the RNA editing efficiency of CRISPR-Cas13b is tested. The GFP reporter system for RNA editing is based on a GFP reporter gene with a stop codon at W58 position (GFP-W58X), such as Marina et al., (2020), reported in " Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing " (Cell Reports 33, 108350). RNA editing is carried out at W58X position to repair the W58 codon, restore its function, and result in the production of functional fluorescent protein in the cell.
[0101] The GFP-W58X gene is cloned into a lentiviral vector containing an LSS-mKate2 fluorescent reporter gene, which is used for cell selection. The crRNA targeting the W58X position is cloned into a pC0043 plasmid (pC0043-GFP-W58X) to be delivered to cells by transfection. The dCas13bADAR2DD gene is cloned from pC0053 and transferred to a pLenti-CMVt vector, which carries the mCherry gene on a lentiviral vector for cell selection. The GFP-W58X gene in the lentiviral vector is then delivered to 293F-rtTA3 cells. Cells expressing LSS-mKate2 fluorescence are sorted using fluorescence-activated cell sorting (FACS). Subsequently, 293F-rtTA3-GFP-W58X cells were transfected with plasmids pC0043-GFP-W58X and pLenti-CMVt-dCas13bADAR2DD-mCherry, and the cells were cultured for 4 days before being collected for analysis of GFP fluorescence levels.
[0102] Figure 13 The experimental results show that when using the crRNA targeting W58X, the modification of dCas13bADAR2DD on the R570P position of Cas13b can improve RNA editing efficiency, which is about doubled compared to the original dCas13bADAR2DD. However, when using non-targeted crRNA (the non-targeted crRNA can not perform RNA editing at the stop codon), there is no significant difference in the RNA editing efficiency of WT and R570P Cas13b. Therefore, the result shows that R570P can be used to enhance the efficiency of the CRISPR-Cas13 system that is functionally independent of the nuclease domain in a specific and targeted manner.
[0103] Example 5: Amino acid modifications in other regions of R570P Cas13b can further enhance the efficiency of the CRISPR-Cas13b system in eukaryotic cells.
[0104] according to Figure 7 and Figure 8 Based on the experimental results, in addition to R570P, other mutations can be combined with R570P to further improve the efficiency of the CRISPR-Cas13 system. Additional mutations were introduced into R570P Cas13b to test whether they can enhance the RNA targeting function of Cas13b. Figure 7 and Figure 8 Assays using dengue reporter virus showed that R570P Cas13b had already strongly suppressed mCherry expression to near baseline levels, so a new test system was used that used the mCherry gene under the constitutive expression control of the PGK promoter. Another crRNA was also used that only partially suppressed mCherry expression even with R570P Cas13b. Figure 7 and Figure 8 Compared to the system used, this new test system allows for better measurement of the improvement in efficiency of additional mutations, as the inhibition level of R570P is still distinguishable from the baseline. The evaluation was performed in K562-rtTA3 cells with PGK-mCherry, and the activity level of mutant Cas13b was measured using flow cytometry. The Cas13b mutant gene and crRNA box were delivered to the cells using a lentiviral vector. The cells were sorted by FACS, and the K562 cells containing both Cas13b and crRNA were selected based on the fluorescence of GFP and miRFP703. Subsequently, the induction of Cas13b expression was completed with four days of doxycycline (1 μg / ml), and the fluorescence level of mCherry was then assessed by flow cytometry.
[0105] Figure 14 The results presented show that the efficiency of R570PCas13b can be enhanced by nearly twofold through the addition of mutations D323P and N769V. Notably, both modifications are located within the HEL1 and HEL2 domains, which do not serve as the nuclease domain of Cas13b. This experimental result highlights R570P Cas13b as a promising basis for improving the efficiency of CRISPR-Cas13b systems in eukaryotic cells.
[0106] Best Mode for Carrying Out the Invention
[0107] As described in the "Summary of the Invention" topic.
Claims
1. A mutated Cas13b gene, characterized in that The amino acid modification of the Cas13b gene is at at least one position selected from the group consisting of: 273, 323, 343, 556, 570, 601, 625, 769, 967, 989 and 990.
2. the Cas13b gene of mutation according to claim 1, wherein said amino acid modification is achieved by a method selected from replacement, deletion and addition.
3. the Cas13b gene of mutation according to claim 2, wherein by the amino acid modification of replacement be selected from at least one amino acid replacement of the group being made up of the following: S273R, K601L, R570P, Y343L, T625G, N769V, K990V, K990A, D323P, I967L, N989H and T566E.
4. according to the Cas13b gene of the mutation described in any one of claim 1-3, wherein the Cas13b gene is derived from the bacterium selected from the following: Prevotella species (Prevotella sp.) (PspCas13b), Capnocytophaga canimorsus (CcaCas13b), cheek Prevotella (Prevotella buccae) (PbuCas13b), Porphyromonas gingivalis (Porphyromonas gulae) (PguCas13b), Prevotella species (PsmCas13b) and Riemerella anatipestifer (RanCas13b).
5. A plasmid set for delivering a mutated Cas13b gene to cells, comprising: a. A mutant Cas13b gene, characterized in that The amino acid modification of the Cas13b gene is at at least one position selected from the group consisting of: 273, 323, 343, 556, 570, 601, 625, 769, 967, 989 and 990, b. Lentiviral vector, The mutated Cas13b gene is constructed into a lentiviral vector.
6. A plasmid set for delivering a mutated Cas13b gene to a cell according to claim 5, further comprising: a. a polyadenylic acid tail signal connected to the mutated Cas13b gene, and b. A gene set for producing a luminescent protein for tracking cells that receive the mutated Cas13b gene.
7. The plasmid set of the Cas13b gene for the mutation of gene delivery to cells according to claim 6, wherein the luminescent protein is selected from green fluorescent protein (eGFP), red fluorescent protein (mCherry) and infrared fluorescent protein (miRFP703).
8. A plasmid set of mutated Cas13b genes for gene delivery to cells according to claim 5, wherein the Cas13b gene is derived from a bacterium selected from the group consisting of: Prevotella species (PspCas13b), Prevotella species (PspCas13b), Capnocytophaga canimorsus (CcaCas13b), Prevotella cheek (PbuCas13b), Porphyromonas gingivalis (PguCas13b), Prevotella species (PsmCas13b) and Riemerella anatipestifer (RanCas13b).
9. A protein delivery system for introducing a mutant Cas13b protein into a target cell, comprising: a. virus-like particles (VLPs), and b. Cas13b-crRNA ribonucleoprotein complex comprising a mutant Cas13b protein, a CRISPR-Cas13 system, and an RNA payload in the form of a ribonucleoprotein complex from a mutant Cas13b gene, characterized in that: The amino acid modification of the Cas13b gene is at at least one position selected from the group consisting of: 273, 323, 343, 556, 570, 601, 625, 769, 967, 989 and 990.
10. A protein delivery system for introducing a mutated Cas13b protein into a target cell according to claim 9, wherein the virus-like particle comprises: a. a capsid protein from murine leukemia virus, which is used to encapsulate a specific Cas13b protein, and b. a cell membrane from 293T cells, wherein the cell membrane has a surface protein specific to a target cell, wherein the surface protein is used to allow the virus-like particles to bind to the target cell, The encapsulated specific Cas13b protein and murine leukemia virus are capable of binding to surface proteins specific to target cells.
11. The protein delivery system for importing mutated Cas13b protein into target cells according to claim 10, wherein the target cell is a eukaryotic cell.
12. The protein delivery system for importing a mutated Cas13b protein into a target cell according to claim 9, wherein the Cas13b gene is derived from a bacterium selected from the group consisting of: Prevotella species (PspCas13b), Prevotella species (PspCas13b), Capnocytophaga canimorsus (CcaCas13b), Prevotella cheeks (PbuCas13b), Porphyromonas gingivalis (PguCas13b), Prevotella species (PsmCas13b), and Riemerella anatipestifer (RanCas13b).
